Company / R&D Expense
CG Oncology, Inc. R&D Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$116.6M
FY2025
5-year range
$45.8M / $116.6M
FY2023-FY2025
Trend
+42.1%
vs FY2024
Sector context
#131 of 210
Health Care
What the data says
At $117M, CG Oncology, Inc.'s r&d expense ranks #131 of 210 in the Health Care sector. Improved from $46M to $117M over the past 2 years.
Based on SEC 10-K filings.
$117M in FY2025.
Improved from $46M to $117M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#131 of 210 in Health CareTop 62% of 210This company $116.6M Sector average $644.1M
▼
-81.9% below sector average
Key checks
Key Insights
- In FY2025, r&d expense increased 42.1% year-over-year.
- Ranks #131 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 8.02 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $116.6M | +42.1% |
| FY2024 | $82.1M | +79.5% |
| FY2023 | $45.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026